tiprankstipranks
Trending News
More News >

Bolt Biotherapeutics Announces Reverse Stock Split

Story Highlights
Bolt Biotherapeutics Announces Reverse Stock Split

Confident Investing Starts Here:

The latest announcement is out from Bolt Biotherapeutics ( (BOLT) ).

On June 6, 2025, Bolt Biotherapeutics implemented a one-for-twenty reverse stock split of its common stock, following approval from stockholders and the Board of Directors on May 27, 2025. This move affects the company’s outstanding shares, equity incentive plans, and stock options, with trading on a split-adjusted basis set to begin on June 9, 2025, on the Nasdaq Capital Market under the ticker ‘BOLT’.

The most recent analyst rating on (BOLT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Bolt Biotherapeutics stock, see the BOLT Stock Forecast page.

Spark’s Take on BOLT Stock

According to Spark, TipRanks’ AI Analyst, BOLT is a Neutral.

Bolt Biotherapeutics faces significant challenges in financial performance and valuation, with ongoing losses impacting its attractiveness to investors. The technical analysis shows bearish signals, suggesting weak market sentiment. Structural improvements are necessary for enhancing financial health and stock performance.

To see Spark’s full report on BOLT stock, click here.

More about Bolt Biotherapeutics

Bolt Biotherapeutics, Inc. operates in the biotechnology industry, focusing on developing immuno-oncology therapeutics.

Average Trading Volume: 334,724

Technical Sentiment Signal: Sell

Current Market Cap: $12.41M

See more insights into BOLT stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App